Difference between revisions of "Aminoglutethimide (Cytadren)"
Jump to navigation
Jump to search
(updated content) |
m |
||
| (20 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
| − | |||
==General information== | ==General information== | ||
| − | Class/mechanism: Inhibitor of adrenalcortical steroid synthesis, blocks conversion of cholesterol to pregnenolone and subsequent synthesis of adrenal steroids, has aromatase inhibitor activity.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/018202s021lbl.pdf Aminoglutethimide (Cytadren) package insert]</ref><ref>[[ | + | Class/mechanism: Inhibitor of adrenalcortical steroid synthesis, blocks conversion of cholesterol to pregnenolone and subsequent synthesis of adrenal steroids, has aromatase inhibitor activity.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/018202s021lbl.pdf Aminoglutethimide (Cytadren) package insert]</ref><ref>[[:File:Aminoglutethimide.pdf | Aminoglutethimide (Cytadren) package insert (locally hosted backup)]]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://reference.medscape.com/drug/cytadren-aminoglutethimide-342878 Medscape], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
| + | |||
| + | ==Diseases for which it was used== | ||
| + | *[[Breast cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[ | + | *[https://chemocare.com/druginfo/aminoglutethimide.aspx Aminoglutethimide (Cytadren) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/aminoglutethimide.aspx Aminoglutethimide (Cytadren) patient drug information (Chemocare)]</ref> |
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | ''This medication does not have a specific cancer indication; it is indicated for Cushing Syndrome.'' | ||
| + | *1980-10-29: Initial approval | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Brand names:''' Aminoblastin, Cytadren, Elipten, Orimentin, Orimeten, Orimetene, Rodazol | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drugs]] | ||
| + | [[Category:Oral medications]] | ||
| + | |||
| + | [[Category:Steroid synthesis inhibitors]] | ||
| + | [[Category:Aromatase inhibitors, first generation]] | ||
| + | [[Category:Breast cancer medications (historic)]] | ||
| + | |||
| + | [[Category:FDA approved in 1980]] | ||
Latest revision as of 15:08, 17 November 2023
General information
Class/mechanism: Inhibitor of adrenalcortical steroid synthesis, blocks conversion of cholesterol to pregnenolone and subsequent synthesis of adrenal steroids, has aromatase inhibitor activity.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it was used
Patient drug information
History of changes in FDA indication
This medication does not have a specific cancer indication; it is indicated for Cushing Syndrome.
- 1980-10-29: Initial approval
Also known as
- Brand names: Aminoblastin, Cytadren, Elipten, Orimentin, Orimeten, Orimetene, Rodazol